Holen Sie sich die Stockscreener-App
247.72
1.45%
3.55
Handel nachbörslich:
249.90
2.18
+0.88%
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
JAZZ Maintains Rating by Truist Securities -- Price Target Lowered to $254 - GuruFocus
Sleep Apnea Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart.com
Jazz Pharmaceuticals Holds Steady Near Resistance as Volume Patterns Signal CautionQuality Factor - dars.gov.et
Jazz Pharmaceuticals PLC at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
JAZZJazz Pharmaceuticals plc Options - Finviz
Jazz Pharmaceuticals (JAZZ) Breakout Keeps Valuation In Focus Following Zepzelca Setback And Ziihera Hopes - simplywall.st
Jazz Pharmaceuticals (JAZZ) EVP reports RSU tax withholding and retains 47,911 shares - Stock Titan
Jazz Pharmaceuticals (JAZZ) CEO shares withheld to cover RSU tax obligations - Stock Titan
Jazz Pharmaceuticals (JAZZ) insider RSU tax withholding detailed - Stock Titan
Jazz Pharmaceuticals (JAZZ) CFO reports 3,343-share tax withholding - Stock Titan
Jazz Pharmaceuticals (JAZZ) Price Forecast: Will Breakout Confirm Higher Highs? - FXEmpire
Jazz Pharmaceuticals stock hits all-time high at 243.39 USD - Investing.com
Jazz Pharmaceuticals stock hits all-time high at 243.39 USD By Investing.com - Investing.com UK
Form 144 Jazz Pharmaceuticals Plc For: 1 July By Investing.com - Investing.com Nigeria
Bruce Cozadd files Form 144 to sell shares — Jazz Pharmaceuticals (NASDAQ: JAZZ) - Stock Titan
Enterprise value to revenue forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView
Price to earnings forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView
Price to book forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView
Is Jazz Pharmaceuticals (JAZZ) Using AbCellera Deal to Quietly Redefine Its Oncology Strategy? - simplywall.st
3 Overrated Stocks Walking a Fine Line - Yahoo Finance UK
Price to sales forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView
Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? - TradingView
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks - AOL.com
Erica Jefferson Joins Jazz Pharmaceuticals as Chief Communications Officer - hrtoday.in
JAZZ Forecast — Price Target — Prediction for 2027 - TradingView
Jazz Pharmaceuticals' lung cancer drug setback in late-stage trials: Here's why the stock impact may be more limited than it looks - MSN
Jazz Pharma announces late-stage trial setback for lung cancer therapy - MSN
Jazz Pharmaceuticals Public Limited Company Actuals & Estimates (NASDAQ:JAZZ) - TradingView
Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade) (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals (JAZZ) Reframed Zepzelca Growth, Is The Stock Still Below Fair Value? - simplywall.st
Strong Leaders Build Strong Teamsand Strong Teams Change Patients’ LivesJazz Pharmaceuticals - Oncodaily
Jazz Pharmaceuticals PLC (HAM:J7Z) Stock Price, Trades & News - GuruFocus
Jazz Pharmaceuticals (JAZZ) Stock Gets Fair Value Boost As Ziihera Views Split Analysts - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Expands AbCellera Tie Up As Zepzelca Trial Misses Goal - Yahoo Finance
Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) Announce Collaboration - Yahoo Finance UK
Will Zepzelca’s Failed LAGOON Trial in Second-Line SCLC Change Jazz Pharmaceuticals' (JAZZ) Narrative? - simplywall.st
JAZZ’s Zepzelca fails to meet primary goal in lung cancer study - MSN
Investor Outlook: Jazz Pharmaceuticals Plc (JAZZ) And Its 14.40% Potential Upside - DirectorsTalk Interviews
Jazz Pharmaceuticals PLC (JAZZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jazz Pharmaceuticals (JAZZ) Stock Could Be 73% Below Fair Value After Recent Pullback - simplywall.st
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies - Yahoo Finance
A potential billion-dollar deal looks for new ways to beat back cancer - The Business Journals
Jazz and AbCellera sign deal for T-cell engagers in solid tumours - Pharmaceutical Technology
Jazz Pharmaceuticals PLC (JAZZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Jazz Pharmaceuticals PLC (JAZZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jazz Pharmaceuticals PLC (JAZZ) Institutional Confidence - TradingKey
Jazz Pharmaceuticals PLC (JAZZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jazz Pharmaceuticals PLC (JAZZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jazz Pharmaceuticals PLC (JAZZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jazz Pharmaceuticals PLC (JAZZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Insider Sell: Mark Smith Sells Shares of Jazz Pharmaceuticals PL - GuruFocus
AbCellera (NASDAQ: ABCL) inks Jazz cancer antibody pact with $56M upfront, big milestones - Stock Titan
Jazz taps Abcellera in potential $4B antibody discovery deal - BioWorld News
Jazz Pharmaceuticals, AbCellera announce oncology deal - grafa.com
Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4B - BioSpace
Jazz Pharmaceuticals, AbCellera partner on cancer antibodies By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals, AbCellera partner on cancer antibodies - Investing.com UK
Jazz Pharmaceuticals and AbCellera Partner on Antibody Programs for Solid Tumors - Yahoo Finance
Jazz Pharmaceuticals plc And AbCellera Biologics Inc Announces Collaboration To Discover Next-Generation T-Cell Engaging Multispecific Antibodies - marketscreener.com
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):